دیێنۆجێست

دیێنۆجێست، لەژێر ناوی بازرگانی ( Visanne ڤیسانێ) دەفرۆشرێت لەنێوان ئەوانی تر، دەرمانێکی پرۆجستینە کە بەکارھاتووە بۆ کۆنتڕۆلی دووگیانی لە چارەسەری حاڵەتی (endometriosis) ^[١]^[٢]^[٣]^[٤]^[٥]^[٦] ھەروەھا بۆ چارەسەری سووری مانگانەش بەکارھاتووە وە بۆ چارەسەری سەر سوڕی مانگانەی سەخت ^[٤]^[٧]^[٨] دەرمانەکە بەتەنھا و لەگەل تێکەلی ئیسترۆجینیش بەردەستە^[٩]^[٧] وە لە ڕێگەی دەمەوە بەکاردێت^[٣] کاریگەریە لاوەکیەکانی بریتیە لە سەرئێشە ، دڵ تێکەلھاتن، ئازاری مەمک، خەمۆکی، زیپکە، لە نێوان ئەوانی تر^[١٠] دەرمانەکە پرۆجێستۆجینە وە چالاکاری (وەرگرەکانی پڕۆجێستۆجینە) کە ئامانج دەخاتە سەر پڕۆجێسترۆن^[٣]^[١١] پڕۆجێستۆجینێکی بێ ھاوتایە بە کاریگەریەکی بەھێز لە مناڵدان^[١١] دەرمانەکە ھەندێک چالاکی دژە ئەندرۆجینی ھەیە کە لەوانەیە یارمەتی باشبوونی حاڵەتی ( ئەندرۆجینی زاڵبوو ) بدات لە جەستەدا وەکوو زیپکە، ھیچ چالاکیەکی تری ھۆرمۆنی نیە^[٣]^[١١]^[٢]^[١٢]^[١٣]

دیێنۆجێست لە ١٩٧٩ دۆزرایەوە وە ناسێنرا بۆ بەکارھێنانی لە پزیشکیدا لە ١٩٩٥^[١٤]^[١٥]^[١٦] پێکھاتە زیادکراوەکانی تری دیێنۆجێست لەنێوان ٢٠٠٧ و ٢٠١٠ پەسەند کرا^[٦]^[١٧] ھەنێک جار بە "نەوەی-چوارەم" ی پڕۆجستین باسی دەکرێ^[١٨]^[١٩] دەرمانەکە بە فراوانی لە جیھان بەردەستە و دەفرۆشرێ^[٩]

سەرچاوەکان[دەستکاری]

دەروازەی زانست

^ http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04227-3
^ ^ئ ^ا http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04227-3
^ ^ئ ^ا ^ب ^پ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.
^ ^ئ ^ا "Dienogest - Bayer HealthCare Pharmaceuticals/Mochida Pharmaceutical - AdisInsight".
^ Tommaso Falcone; William W. Hurd (22 May 2013). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer Science & Business Media. pp. 300–. ISBN 978-1-4614-6837-0. Dienogest is a 19-nortestosterone derivative that is approved in the European Union for the treatment of endometriosis. It is not available in the United States as a separate drug. It is only available in the oral contraceptive Natazia (Bayer Pharmaceuticals, Montville, NJ, USA) (estradiol valerate/dienogest), which is a newer four-phasic pack that contains dienogest.
^ ^ئ ^ا McCormack PL (2010). "Dienogest: a review of its use in the treatment of endometriosis". Drugs. 70 (16): 2073–88. doi:10.2165/11206320-000000000-00000. PMID 20964453.
^ ^ئ ^ا Bartsch, V., & Römer, T. (2015). Gynaecological uses of dienogest alone and in combination with oestrogens. http://www.jmdrev.com/fileadmin/user_upload/Medien-Dateien/JMDR_Dienogest_E_2015.pdf
^ Micks EA, Jensen JT (2013). "Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill". Adv Ther. 30 (1): 1–13. doi:10.1007/s12325-012-0071-3. PMID 23239397. S2CID 31125733.
^ ^ئ ^ا "Dienogest".
^ "Dienogest". Aust Prescr. 38 (4): 138–9. 2015. doi:10.18773/austprescr.2015.050. PMC 4653971. PMID 26648643.
^ ^ئ ^ا ^ب Ruan X, Seeger H, Mueck AO (April 2012). "The pharmacology of dienogest". Maturitas. 71 (4): 337–44. doi:10.1016/j.maturitas.2012.01.018. PMID 22364708.
^ Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.
^ Regidor PA, Schindler AE (2017). "Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone". Oncotarget. 8 (47): 83334–83342. doi:10.18632/oncotarget.19833. PMC 5669973. PMID 29137347.
^ Menzenbach B; Hübner M; K. Ponsold (1984). "Untersuchungen zur Bromierung/Dehydrobromierung von 17-Cyanmethyl-17-hydroxy-östr-5(10)-en-3-on". Journal für Praktische Chemie. 326 (6): 893–898. doi:10.1002/prac.19843260606.
^ Kaufmann G, Dautzenberg H, Henkel H, et al. (August 1999). "Nitrile hydratase from Rhodococcus erythropolis: metabolization of steroidal compounds with a nitrile group". Steroids. 64 (8): 535–40. doi:10.1016/S0039-128X(99)00028-8. PMID 10493599. S2CID 21769309.
^ "Archived copy". Archived from the original on 2008-03-07. Retrieved 2008-01-18.{{cite web}}: CS1 maint: archived copy as title (link)
^ Guida M, Bifulco G, Di Spiezio Sardo A, Scala M, Fernandez LM, Nappi C (2010). "Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill". International Journal of Women's Health. 2: 279–90. doi:10.2147/IJWH.S6954. PMC 2990895. PMID 21151673.
^ Paula Briggs; Gabor Kovacs (11 July 2013). Contraception: A Casebook from Menarche to Menopause. Cambridge University Press. pp. 52–. ISBN 978-1-107-43611-4.
^ Howard J.A. Carp (9 April 2015). Progestogens in Obstetrics and Gynecology. Springer. pp. 112–113, 170–. ISBN 978-3-319-14385-9.

[VisanneLabel-1] ttp://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04227-3

[VisanneLabel2-2] ئ ^ا http://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-04227-3

[pmid16112947-3] ئ ^ا ^ب ^پ Kuhl H (2005). "Pharmacology of estrogens and progestogens: influence of different routes of administration" (PDF). Climacteric. 8 Suppl 1: 3–63. doi:10.1080/13697130500148875. PMID 16112947. S2CID 24616324.

[AdisInsight-4] ئ ^ا "Dienogest - Bayer HealthCare Pharmaceuticals/Mochida Pharmaceutical - AdisInsight".

[FalconeHurd2013-5] Tommaso Falcone; William W. Hurd (22 May 2013). Clinical Reproductive Medicine and Surgery: A Practical Guide. Springer Science & Business Media. pp. 300–. ISBN 978-1-4614-6837-0. Dienogest is a 19-nortestosterone derivative that is approved in the European Union for the treatment of endometriosis. It is not available in the United States as a separate drug. It is only available in the oral contraceptive Natazia (Bayer Pharmaceuticals, Montville, NJ, USA) (estradiol valerate/dienogest), which is a newer four-phasic pack that contains dienogest.

[pmid20964453-6] ئ ^ا McCormack PL (2010). "Dienogest: a review of its use in the treatment of endometriosis". Drugs. 70 (16): 2073–88. doi:10.2165/11206320-000000000-00000. PMID 20964453.

[BartschRomer2015-7] ئ ^ا Bartsch, V., & Römer, T. (2015). Gynaecological uses of dienogest alone and in combination with oestrogens. http://www.jmdrev.com/fileadmin/user_upload/Medien-Dateien/JMDR_Dienogest_E_2015.pdf

[pmid23239397-8] Micks EA, Jensen JT (2013). "Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill". Adv Ther. 30 (1): 1–13. doi:10.1007/s12325-012-0071-3. PMID 23239397. S2CID 31125733.

[Drugs.com-9] ئ ^ا "Dienogest".

[pmid26648643-10] "Dienogest". Aust Prescr. 38 (4): 138–9. 2015. doi:10.18773/austprescr.2015.050. PMC 4653971. PMID 26648643.

[pmid22364708-11] ئ ^ا ^ب Ruan X, Seeger H, Mueck AO (April 2012). "The pharmacology of dienogest". Maturitas. 71 (4): 337–44. doi:10.1016/j.maturitas.2012.01.018. PMID 22364708.

[pmid12600226-12] Raudrant D, Rabe T (2003). "Progestogens with antiandrogenic properties". Drugs. 63 (5): 463–92. doi:10.2165/00003495-200363050-00003. PMID 12600226. S2CID 28436828.

[pmid29137347-13] Regidor PA, Schindler AE (2017). "Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestogens: dienogest and drospirenone". Oncotarget. 8 (47): 83334–83342. doi:10.18632/oncotarget.19833. PMC 5669973. PMID 29137347.

[MenzenbachHubner1984-14] Menzenbach B; Hübner M; K. Ponsold (1984). "Untersuchungen zur Bromierung/Dehydrobromierung von 17-Cyanmethyl-17-hydroxy-östr-5(10)-en-3-on". Journal für Praktische Chemie. 326 (6): 893–898. doi:10.1002/prac.19843260606.

[pmid10493599-15] Kaufmann G, Dautzenberg H, Henkel H, et al. (August 1999). "Nitrile hydratase from Rhodococcus erythropolis: metabolization of steroidal compounds with a nitrile group". Steroids. 64 (8): 535–40. doi:10.1016/S0039-128X(99)00028-8. PMID 10493599. S2CID 21769309.

[Jenapharm-16] "Archived copy". Archived from the original on 2008-03-07. Retrieved 2008-01-18.{{cite web}}: CS1 maint: archived copy as title (link)

[pmid21151673-17] Guida M, Bifulco G, Di Spiezio Sardo A, Scala M, Fernandez LM, Nappi C (2010). "Review of the safety, efficacy and patient acceptability of the combined dienogest/estradiol valerate contraceptive pill". International Journal of Women's Health. 2: 279–90. doi:10.2147/IJWH.S6954. PMC 2990895. PMID 21151673.

[BriggsKovacs2013-18] Paula Briggs; Gabor Kovacs (11 July 2013). Contraception: A Casebook from Menarche to Menopause. Cambridge University Press. pp. 52–. ISBN 978-1-107-43611-4.

[Carp2015-19] Howard J.A. Carp (9 April 2015). Progestogens in Obstetrics and Gynecology. Springer. pp. 112–113, 170–. ISBN 978-3-319-14385-9.

[١]

[٢]

[٣]

[٤]

[٥]

[٦]

[٧]

[٨]

[٩]

[١٠]

[١١]

[١٢]

[١٣]

[١٤]

[١٥]

[١٦]

[١٧]

[١٨]

[١٩]